Navigation Links
Bionovo Announces First Quarter 2009 Highlights and Financial Results
Date:5/7/2009

EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2009.

Company Highlights

  • Bionovo presented data on a preclinical anti-cancer drug candidate, BN108, at the American Association of Cancer Research (AACR) conference in April. TspA3 has been identified as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mTOR kinases in breast cancer cells but not in normal cells.
  • Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake Gustafsson and Bert W. O'Malley.
  • The Company continues to work towards satisfying the FDA's requests for clarification of the manufacturing and analytical strategy to be used in ensuring the consistency of its drug products.
  • The Company continues to pursue a wide variety of funding options including government grants, partnering, and debt and equity offerings.

First Quarter Results

Total operating expenses for the three months ending March 31, 2009 were $4.6 million compared to $4.2 million for the same period in 2008. Total operating expenses for the first quarter included one-time expenses associated with the relocation of the Company's headquarters, the purchase of raw materials for manufacturing purposes throughout the year, and severance costs. The Company expects operating expenses to decrease in the second quarter.

The Company reported a net loss for the three months ended March 31, 2009 of $4.7 million, or $0.06 per share, compared with a net loss of $3.9 million, or $0.05 per share,
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... With the NCAA set to undergo ... an interview with Yale University Associate Athletic Director Steve ... approach to ensuring student-athlete experience that is consistent with ... a number of key factors that contribute to a ... factor in creating this culture seems simple at first. ...
(Date:8/31/2014)... tea reduces non-cardiovascular mortality by 24%, reveals a study ... by Professor Nicolas Danchin from France. , Professor Danchin ... coffee it,s probably better to drink tea. Coffee and ... Their effects on cardiovascular (CV) health have been investigated ... the effects of coffee and tea on CV mortality ...
(Date:8/30/2014)... Barcelona, Spain Sunday 31 August 2014: A ... and safe in a real world setting, according ... by Dr Stylianos Pyxaras from Germany. The direct ... features that improve operator control and has the ... outcomes in patients with severe aortic stenosis. , ...
(Date:8/30/2014)... 31, 2014 Not only is USHEALTH Advisors ... has just recorded its highest level of late-summer sales, including ... company is going to set a new record in 2014,” ... “Our growth in both weekly annualized volume and the ... last week of August, we saw even more of our ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, ... a best-seller within golf and tennis. Golfers and tennis players ... most by using the compression elbow sleeve to help treat ... condition that causes pain on the inner side of your ... the bony bump on the inside of your elbow. The ...
Breaking Medicine News(10 mins):Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2
... are less likely to develop high blood pressure say researchers ... the study researchers analyzed data from two large studies, which ... women questionnaires, which asked about their folate and supplemental folic ... at the start of the study. It was found that ...
... suggest people who carry a gene that produces a ... small increased risk for stroke.// ,Researchers reviewed medical ... found that previous study results were observational in nature. ... confounding factors by looking at data on the link ...
... a recent study researchers have linked breathing cancer-causing compounds ... cancer among offspring. They also believe that nearly all ... mother’s inhalation of noxious substances. ,The study compared ... and younger who died from leukemia and other cancers ...
... Men who receive a common therapy after prostate cancer surgery ... based on // findings of a recent study. For ... therapy suffered a broken bone within five years of diagnosis, ... receive the treatment. ,Androgen-deprivation therapy has traditionally been given ...
... Several studies have linked the use of estrogen replacement therapy ... mineral density( BMD ) is known as a good indicator ... men to determine how BMD related to the risk of ... decline at the beginning of the study. Researchers then measured ...
... Previous studies have shown inhaled corticosteroids can reduce the ... However, results from a study conducted by researchers from ... more than 2,650 patients with COPD who were prescribed ... 90-day period. Nearly 5,400 patients who had never used ...
Cached Medicine News:
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Red Lens Maddox...
Maddox Rod, short handle (12cm)...
Medicine Products: